RUBRA MEDICAMENTS LIMITED

Statement of Standalone Unaudited Finanical Results for the quarter and Half year ended September 30, 2019

(Rs. in Lakhs)

Percentage Per								(Rs. in Lakhs)
Revenue from Operations	Sr.No.	Particulars	months ended	preceeding 3 months ended	corresponding 3 months ended in the previous year	for current period ended	previous period ended	
1 Revenue from Operations								
II Total Income (+1)			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
II Total Income (+1)								
III Total Income (i + ii) 14.00 9.26 9.09 23.36 18.18 59.11	- 1							59.12
V Spenses								
Cost of Materials Consumed Doct of Materials Consumed Doct Doct			14.00	9.26	9.09	23.26	18.18	59.12
Purchases of Stock in Trade	IV		0.00	0.00	0.00	0.00	0.00	0.00
Changes in Inventories of finished goods, work-in- progress and tock in trade Employee benefits Expense 2.41								
Improgress and stock in trade			10.00	0.00	9.00	10.00	18.00	32.75
Employee benefits Expenses			0.00	0.00	0.00	0.00	0.00	0.00
Finance Costs 0.02		-						
Object O								20.80
Other Expenses								
Total Expenses (IV)		·						
V Profit (loss) before exceptional items and tax (III-IV) 0.78 1.15 4.97 1.93 -7.02 .18.2								
V Exceptional Items		Total Expenses (IV)	13.22	8.11	14.06	21.33	25.20	77.37
VIII Tax Expense:	V	Profit / (loss) before exceptional items and tax (III-IV)			_	1.93	-7.02	
VIII Tax Expense:								17.11
(1) Current tax	VII		0.78	1.15	-4.97	1.93	-7.02	-1.14
(2) Deferred tax 0.00 0.	VIII							
Profit (Loss) for the period from continuing operations 1.15 4.97 1.93 7.7.02 1.1.1								0.00
IX VII-VIII			0.00	0.00	0.00	0.00	0.00	0.00
X Profit/(loss) from discontinuing operations 0.00								
XI Tax Expense of discontinuing operations 0.00 0.		,						
Profit/(loss) from Discontinuing operations (after tax 0.00								
XII	XI		0.00	0.00	0.00	0.00	0.00	0.00
Nill Profit / (Loss) for the period (IX+XII) 0.78 1.15 -4.97 1.93 -7.02 -1.15	VII		0.00	0.00	0.00	0.00	0.00	0.00
XIV Other comprehensive income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss XV Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive income for the period) XVI Earnings per equity share (for continuing operation): (1) Basic 0.01 0.02 0.0 0.04 0.00 0.00 XVII Earnings per equity share (for discontinued operation): (1) Basic 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.								
XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period) 0.78 1.15 -4.97 1.93 -7.02 -1.11		Other comprehensive income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified						
Earnings per equity share (for continuing operation): (1) Basic		(XIII+XIV)(Comprising Profit (Loss) and Other	0.78	1.15	-4.97	1.93	-7.02	-1.14
(2) Diluted 0.01 0.02 0.00 0.04 0.00	XVI		0.01	0.03	0.0	0.04	0.00	0.00
XVII Earnings per equity share (for discontinued operation): (1) Basic (2) Diluted 0.00 0.00 0.00 0.00 0.00 0.00 0.00 XVIII Earnings per equity share (for discontinued & continuing operation): (1) Basic 0.01 0.02 0.00 0.04 0.00								
operation): (1) Basic 0.01 0.02 0.00 0.04 0.00 0.0	XVII	Earnings per equity share (for discontinued operation): (1) Basic						0.00
	XVIII	operation):	0.01	0.02	0.00	0.04	0.00	0.00
								0.00

- The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today. The Segment wise details are not applicable to the Company as the Company has no segments.

The result is provisional and unaudited and subject to change, regrouping and restatement.

For Rubra Medicaments Limited

Place: Mumbai Date: November 14, 2019

Abha Kapoor Director (Finance) & CFO DIN: 02799429

RUBRA MEDICAMENTS LIMITED

(Rs. in Lakhs)

			(Rs. in Lakhs)	
	STATEMENT OF ASSE			
		Figures as at the end of current reporting period	Figures as at the end of the previous reporting period	
	Particulars	September 30, 2019	March 31, 2019	
		Unaudited	Audited	
	ASSETS			
1	Non-current assets			
	(a) Property, plant and equipment	1.60	1.69	
	(b) Capital work-in-progress	17.38	-	
	(C) Investment property (d) Goodwill		<u>-</u>	
	(e) Other intangible assets			
	(f) Intangible assets under development		-	
	(g) Biological assets other than bearer plants		-	
	(h) Financial Assets			
	(i) Investments		-	
	(ii) Trade receivables		-	
	(iii) Loans		-	
	(iv) Others (to be specified) - Advances	25.31	-	
	(i) Deferred tax assets (net)		-	
	(j) Other non-current assets	- 44.20	1.60	
2	Total non-current assets Current assets	44.29	1.69	
_	(a) Inventories	-	-	
	(b) Financial Assets			
	(i) Investments		-	
	(ii) Trade receivables	5.90	29.40	
	(iii) Cash and cash equivalents	10.40	13.79	
	(iv) Bank balances other than (iii) above	-	0.21	
	(v) Loans	-	22.35	
	(vi) Others to be specified - Advances	-	-	
	(c)Current tax assets (net)	-	-	
	(d) Other current assets	2.37 18.67	2.37 68.12	
	Total current assets Total assets	62.96	69.81	
1	EQUITY AND LIABILITIES	02.50	03.01	
	Equity			
	(a) Equity share capital	546.83	546.83	
	(b) Other equity	-486.85	-488.79	
	Total equity	59.98	58.04	
	LIABILITIES			
2	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	-	-	
	(ii) Trade payables (iii) Other financial liabilities (other than those		-	
	specified in item (b), to be specified)		_	
	(b) Provisions	+	-	
	(c) Deferred tax liabilities (net)		-	
	(d) Other non-current liabilities		-	
	Total non-current liabilities	-	-	
	Current liabilities		<u> </u>	
	(a) Financial Liabilities			
	(i) Borrowings	0.01	-	
	(ii) Trade payables	0.33	5.95	
	(iii) Other financial liabilities (other than those			
	specified in item ©	-	-	
	(b) Other current liabilities	2.64	5.82	
	(c)Provisions, current (d) Current tax liabilities (Net)	2.04	5.82	
	Total current liabilities	2.98	11.77	
	Total liabilities		11.77	
	Total Equity and Liabilities	62.96	69.81	